91精品黑料吃瓜
Researchers from the University of Ottawa and The Ottawa Hospital have been awarded $1,050,000 million from the Canada Foundation for Innovation to support facilities for manufacturing innovative treatments and vaccines for COVID-19.
The funding will support new equipment and infrastructure at The Ottawa Hospital鈥檚 (BMC), which has been successfully manufacturing therapies using cells, genes and viruses for clinical trials in Canada and abroad for more than 10 years.
The funding will enhance the BMC鈥檚 ability to support projects related to COVID-19, including:
- A clinical trial of a . It is hoped that this experimental therapy may be able to dampen an overactive immune response and help repair lung damage patients with severe COVID-19 infections;
- Antibody-based treatments for high-risk individuals who have been exposed to COVID-19;
- Vaccines for COVID-19, including a .
鈥淥ur Biotherapeutics Manufacturing Centre has already played a crucial role in launching more than 15 world-first clinical trials,鈥 said Dr. Duncan Stewart, Executive Vice-President of Research at The Ottawa Hospital and a professor at the Department of Cellular and Molecular Medicine. 鈥淭oday鈥檚 funding will now allow us to harness this success to help in the global fight against COVID-19.鈥
The funding was announced by the Canada Foundation for Innovation, as part of a national announcement of more than .
For media inquiries:
Paul Logothetis
Media Relations Officer
Cell: 613.863.7221
[email protected]